MedTrace Logo

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

NCT00400426 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-06-19

No results posted yet for this study

Summary

Palliative radiotherapy for head and neck cancer is widely used but the effect and side effects are largely unknown. We will study the effect of short hypofractionated palliative radiotherapy (20 Gy in 4 fractions) on symptom intensity and -frequency as weel as side effects

Conditions

  • Head and Neck Neoplasms
  • Recurrence
  • Neoplasms, Second Primary

Interventions

PROCEDURE

Radiotherapy

20 Gy in 4 fx

Sponsors & Collaborators

  • Danish Head and Neck Cancer Group

    collaborator NETWORK

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Kenneth Jensen, MD · DAHANCA (Danish Head and Neck Cancer Group)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400426 on ClinicalTrials.gov